ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Shionogi Gets Daridorexant’s Japanese D
In VivoThe knockback of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. 's patritumab deruxtecan (DXd) in June, and the late-stage lung cancer misfire of AstraZeneca PLC and Daiichi Sankyo’s datopotamab
ScripAntibody-drug conjugates are big business and major deals have been struck in this area over the past year or so, with companies including Pfizer Inc. , Johnson & Johnson and Merck & Co., Inc. al
Generics BulletinExecutive changes in the off-patent medicines industry throughout 2023 reflected a growing interest in the innovator side of the life sciences sector among leading generics and biosimilars companies.